Recombinant EGFR (Panitumumab Biosimilar) anticorps

N° du produit ABIN7200662

Cet anticorps Souris Monoclonal détecte spécifiquement EGFR (Panitumumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.

Aperçu rapide pour Recombinant EGFR (Panitumumab Biosimilar) anticorps (ABIN7200662)

Antigène: EGFR (Panitumumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp EGFR (Panitumumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Détail du produit anti-EGFR (Panitumumab Biosimilar) anticorps

Fonction: Panitumumab Biosimilar, Human EGFR/ErbB-1/HER1 Monoclonal Antibody

Specificité: The monoclonal antibody panitumumab biosimilar specifically binds to the human EGFR, ErbB-1 and HER1.

Attributs du produit: Recombinant Humanized IgG2 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody panitumumab biosimilar was produced in the Panitumumab biosimilar CHO stable cell line.

Isotype: IgG2 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by panitumumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur EGFR (Panitumumab Biosimilar)

Antigène: EGFR (Panitumumab Biosimilar)

Classe de substances: Biosimilar

Sujet: Panitumumab, a fully anti-EGFR (epidermal growth factor receptor, EGF receptor, ErbB-1 and HER1 in humans) human monoclonal antibody, is used for the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".